Loading
Iovance Biotherapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Jun 2025.
Iovance Biotherapeutics, Inc.: what insiders have been doing
Every trade that managers of Iovance Biotherapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector and is based in San Carlos, United States. It was founded in 2007. Between 18 October 2025 and 18 October 2026, 6 insiders published 36 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (5,814 companies, median 19 filings), a count of 36 filings is above the norm. The full history, which starts in 2022, counts 19 purchases against no sales. The 10-K for the year ended 31 December 2025 shows 263.5 m USD of revenue and -391.0 m USD of net income.
Over the last twelve months, not one insider purchase of Iovance Biotherapeutics, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
120
Thresholds
n/a
Buy Volume
€135M
19 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDaniel Gordon Kirby1 buy
Frederick G. Vogt1 buy
Raj K. Puri1 buy
Since the insiders bought
- +81.0%Entry US$2.21 · Close at T+365 US$4.00
- +145.7%Entry US$1.75 · Close at T+365 US$4.30
- +85.2%Entry US$1.83 · Close at T+365 US$3.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Iovance Biotherapeutics, Inc. Buy (bullish), based on 10 analysts. Average price target: US$14.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,913 of 24,148 companies
25.4
score / 100
Value21
Quality30
FCF yld-5.0%
Earn yld-5.9%
EV/EBITDA·
ROE-40%
Gross mgn34%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.72
Analyst consensus
10 analystsBuy
US$7.00Target US$14.40(-2%)US$20.00
Income statement
RevenueUS$263.5M
Gross profitUS$90.3M34% margin
EBITDA-US$350.9M-133% margin
Net income-US$391M-89.1% margin
Valuation
PER (forward)-75.2x
P/Book9.1x
Beta0.76
Balance sheet & cash
Market capUS$6.7B
Total debtUS$49.4M
Free Cash Flow-US$336.2M
Debt / Equity6%
Profitability & ownership
ROE-40.4%
ROA-20.3%
% insiders0.4%
% institutions70.8%
Last declaration on 10 September 2026
Declarations120 total
7,813 shares0Common StockSEC:0001104659-26-106750:0
9,766 shares0Common StockSEC:0001104659-26-106748:0
3,976 shares@ US$8.700.0007% mcap30.2% of flowCommon StockSEC:0001104659-26-106750:1
4,478 shares@ US$8.700.0008% mcap55.8% of flowCommon StockSEC:0001104659-26-106748:1
15,626 shares0Common StockSEC:0001104659-26-106752:0
6,638 shares@ US$8.700.0012% mcap22.0% of flowCommon StockSEC:0001104659-26-106752:1
4,472 shares@ US$8.280.0007% mcap32.4% of flowCommon StockSEC:0001104659-26-105099:1
8,789 shares0Common StockSEC:0001104659-26-105099:0
5,470 shares0Common StockSEC:0001104659-26-105100:0
2,508 shares@ US$8.280.0004% mcap29.8% of flowCommon StockSEC:0001104659-26-105100:1
17,702 shares@ US$8.280.0029% mcap56.0% of flowCommon StockSEC:0001104659-26-105101:1
41,669 shares0Common StockSEC:0001104659-26-105101:0
2,436 shares@ US$6.400.0003% mcap21.9% of flowCommon StockSEC:0001104659-26-095040:1
10,001 shares0Common StockSEC:0001104659-26-095040:0
49,995 shares0Common StockSEC:0001104659-26-093482:0
21,238 shares@ US$6.210.0027% mcap100.0% of flowCommon StockSEC:0001104659-26-093482:1
7,813 shares0Common StockSEC:0001104659-26-071897:0
7,813 shares0Common StockSEC:0001104659-26-071891:0
3,976 shares@ US$4.230.0005% mcap14.7% of flowCommon StockSEC:0001104659-26-071891:1
3,976 shares@ US$4.230.0005% mcap100.0% of flowCommon StockSEC:0001104659-26-071897:1
8,790 shares0Common StockSEC:0001104659-26-070149:0
4,473 shares@ US$3.9615.5% of flowCommon StockSEC:0001104659-26-070149:1
62,493 shares0Common StockSEC:0001104659-26-024765:0
31,246 shares0Common StockSEC:0001104659-26-024762:0
39,059 shares0Common StockSEC:0001104659-26-024760:0
25 of 120 declarations
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a biopharmaceutical company focused on developing cell therapies for cancer treatment. It specializes in using modified T cells to target and destroy tumor cells.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
